Lilly’s Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions Read more
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology Read more
Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion Read more
New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever Read more
Cleanroom industry experts join the Pharmaceutical Cleanroom Technology Conference in October Read more